Articles Referencing UTHR
Bayer Files Riociguat in Japan - Analyst Blog
5/21/2013, 6:25 pm from Zacks.com in Investing, Business, Stocks
The HealthCare segment of Bayer ( BAYRY ) recently
submitted a regulatory application for its chronic thromboembolic
pulmonary hypertension (CTEPH) candidate, riociguat, in Japan. Bayer... Read >>
Earnings Miss at UTHR - Analyst Blog
4/29/2013, 10:04 am from Zacks.com in Investing, Business, Earnings, Stocks
United Therapeutics Corp. ( UTHR ) reported
first-quarter 2013 earnings of $1.19 per share, well below the
year-ago earnings of $1.29 and the Zacks Consensus Estimate of
$1.47. First... Read >>
United Therapeutics Corp. (UTHR): Today's Most Compelling Stock Buy
4/22/2013, 2:31 pm from David Moenning in Investing, Investing Ideas, Stocks, Technology
SoTM Bull's Eye Report - Today's Most Compelling Buy Monday, April 22, 2013 At StateoftheMarkets.com , we strive to "own the best and ignore the... Read >>
PSTI Plans to Start Phase I Study - Analyst Blog
4/19/2013, 4:11 pm from Zacks.com in Investing, Business, Stocks
Pluristem Therapeutics Inc. ( PSTI ) recently
announced its intention to commence a phase I study that will
evaluate the safety and efficacy of the local administration of
PLacental... Read >>
UTHR to Move PAH Drug into Phase I - Analyst Blog
4/15/2013, 12:11 pm from Zacks.com in Investing, Business, Stocks
United Therapeutics Corporation ( UTHR ) recently gained
approval for the commencement of a phase I study in Australia using
Pluristem Therapeutics Inc. 's ( PSTI ) PLacental
eXpanded... Read >>
Another CRL for UTHR's Oral Remodulin - Analyst Blog
3/26/2013, 4:26 pm from Zacks.com in Investing, Business, Stocks
The US Food and Drug Administration (FDA) recently issued a
second complete response letter (CRL) for United
Therapeutics Corporation's ( UTHR ) new drug
application for oral Remodulin... Read >>
Pipeline Progress at Pluristem - Analyst Blog
3/25/2013, 6:31 pm from Zacks.com in Investing, Business, Stocks
Israel-based Pluristem Therapeutics Inc. ( PSTI ) recently
reported progress on its phase I/II clinical trial, which is
evaluating the safety and efficacy of its PLacental eXpanded... Read >>
Mid-Morning Market Update: Markets Rise On Cyprus Deal, Dollar General Posts Higher Profit
3/25/2013, 11:03 am from Benzinga in Investing, Commodities, Economy, International
Following the market opening Monday, the Dow traded up 0.31
percent to 14,556.33 while the NASDAQ gained 0.41 percent to
3,258.20. The S&P also rose, gaining 0.47 percent to
1,564.17. ... Read >>
Pluristem & UTHR Progress with PLX-PAD - Analyst Blog
3/4/2013, 5:25 pm from Zacks.com in Investing, Business, Stocks
Israel-based Pluristem Therapeutics Inc. ( PSTI ) recently
announced that partner United Therapeutics
Corporation ( UTHR ) intends to
commence a phase I study in Australia using... Read >>
Another Strong Quarter for UTHR - Analyst Blog
2/28/2013, 1:44 pm from Zacks.com in Investing, Business, Stocks
United Therapeutics Corp. ( UTHR ) reported
fourth-quarter earnings of $1.60 per share, well above the year-ago
earnings of 77 cents and the Zacks Consensus Estimate of $1.25.
Higher... Read >>
Ariad Reports in line 4Q Loss - Analyst Blog
2/27/2013, 10:10 am from Zacks.com in Investing, Business, Stocks
Ariad Pharmaceuticals, Inc. ( ARIA ) reported fourth
quarter loss of 36 cents per share, compared with the year-ago loss
of 23 cents per share. The Zacks Consensus Estimate for the... Read >>
Questcor Beats Overall - Analyst Blog
2/27/2013, 10:00 am from Zacks.com in Investing, Business, Stocks
Questcor Pharmaceuticals Inc. ( QCOR ) reported fourth
quarter 2012 adjusted earnings per share of $1.09, up 132% from the
year-ago period. Earnings surpassed the Zacks Consensus Estimate... Read >>
Royalty Pharma Eyes Elan Corp. - Analyst Blog
2/26/2013, 4:40 pm from Zacks.com in Investing, Business, Stocks
Royalty Pharma, a private entity, recently announced its
intention to acquire Elan Corporation, plc ( ELN ). Royalty Pharma
intends to acquire Elan at $11 for every share of Elan and... Read >>
Generic Segment at Mylan Boosted - Analyst Blog
2/26/2013, 4:27 pm from Zacks.com in Investing, Business, Stocks
Mylan Inc. ( MYL ) recently
announced that it has launched its generic version of Lupin
Atlantis Holdings, S.A.'s Antara capsules (fenofibrate - 43 mg and
130 mg). The company started... Read >>
Elan Updates Future Plans - Analyst Blog
2/25/2013, 4:27 pm from Zacks.com in Investing, Business, Stocks
Elan Corporation, plc ( ELN ) recently provided
an update after it announced the restructuring of the Tysabri
collaboration with Biogen Idec ( BIIB ). Notably, Biogen gained full... Read >>